Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
Open Access
- 5 July 2020
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 13 (7) , e235216
Abstract
A patient on a regimen of idelalisib and corticosteroids for a relapse of follicular lymphoma presented to our emergency ward with a fever of unknown origin. Despite the initiation of broad-spectrum antibiotics and fluids, the patient’s clinical condition deteriorated. Eventually, a diagnosis of disseminated cryptococcosis was established and immunophenotyping revealed complete absence of circulating B and CD4+-T lymphocytes, and a markedly diminished CD8+-T lymphocyte count. In this case, treatment with idelalisib and corticosteroids likely resulted in profound lymphopenia and the first reported instance of disseminated cryptococcosis under this regimen. After the withdrawal of idelalisib and steroids and initiation of antifungal therapy, lymphocyte counts partially recovered. After clinical improvement, the patient could be discharged from the hospital. This case highlights that the combination of idelalisib and corticosteroids can cause significant immunocompromise and opportunistic infections. Additionally, we illustrate the rate of lymphocyte reconstitution after withdrawal from idelalisib and corticosteroids.Keywords
This publication has 17 references indexed in Scilit:
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell FunctionThe Journal of Immunology, 2019
- Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)Leukemia, 2019
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemiaHaematologica, 2018
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)Clinical Microbiology and Infection, 2018
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaNew England Journal of Medicine, 2014
- PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humansBlood, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Cryptococcosis in human immunodeficiency virus-negative patientsInternational Journal of Infectious Diseases, 2006
- EFFECT OF CORTICOSTEROIDS ON HUMAN IMMUNE-RESPONSE - COMPARISON OF ONE AND 3 DAILY 1 GM INTRAVENOUS PULSES OF METHYLPREDNISOLONE1978